AbbVie (NYSE:ABBV) Updates Q3 2024 Earnings Guidance
AbbVie (NYSE:ABBV – Get Free Report) updated its third quarter 2024 earnings guidance on Thursday. The company provided EPS guidance of 2.920-2.960 for the period, compared to the consensus EPS estimate of 2.950. The company issued revenue guidance of -. AbbVie also updated its FY 2024 guidance to 10.710-10.910 EPS. AbbVie Price Performance ABBV stock […]
More Stories
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $53.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target reduced by equities researchers at Royal Bank of Canada...
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $53.00
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target reduced by equities researchers at Royal Bank of Canada...
Atmos Energy Co. (NYSE:ATO) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Atmos Energy Co. (NYSE:ATO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the...
Atmos Energy Co. (NYSE:ATO) Given Consensus Rating of “Moderate Buy” by Analysts
Shares of Atmos Energy Co. (NYSE:ATO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the...
Analysts Set Tidewater Inc. (NYSE:TDW) Price Target at $111.25
Tidewater Inc. (NYSE:TDW – Get Free Report) has received an average rating of “Buy” from the five ratings firms that...
Analysts Set Tidewater Inc. (NYSE:TDW) Price Target at $111.25
Tidewater Inc. (NYSE:TDW – Get Free Report) has received an average rating of “Buy” from the five ratings firms that...